SG Americas Securities LLC lifted its position in China Cord Blood Corporation (NYSE:CO) by 131.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 231,204 shares of the medical research company’s stock after buying an additional 131,204 shares during the quarter. SG Americas Securities LLC owned about 0.32% of China Cord Blood Corporation worth $2,571,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CO. Parametrica Management Ltd grew its stake in shares of China Cord Blood Corporation by 1,842.1% in the third quarter. Parametrica Management Ltd now owns 304,903 shares of the medical research company’s stock valued at $3,391,000 after buying an additional 289,203 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of China Cord Blood Corporation in the second quarter valued at $2,316,000. Spark Investment Management LLC grew its stake in shares of China Cord Blood Corporation by 273.9% in the second quarter. Spark Investment Management LLC now owns 114,800 shares of the medical research company’s stock valued at $1,088,000 after buying an additional 84,100 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of China Cord Blood Corporation by 6.5% in the first quarter. Renaissance Technologies LLC now owns 859,500 shares of the medical research company’s stock valued at $5,724,000 after buying an additional 52,700 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of China Cord Blood Corporation in the second quarter valued at $493,000. 8.87% of the stock is owned by institutional investors and hedge funds.

China Cord Blood Corporation (NYSE:CO) opened at $11.60 on Thursday. China Cord Blood Corporation has a 52-week low of $4.27 and a 52-week high of $14.95. The company has a market cap of $1,415.89, a price-to-earnings ratio of 33.54 and a beta of 0.95.

China Cord Blood Corporation (NYSE:CO) last released its quarterly earnings data on Wednesday, August 23rd. The medical research company reported $0.09 EPS for the quarter. China Cord Blood Corporation had a net margin of 26.79% and a return on equity of 9.68%. The firm had revenue of $33.07 million during the quarter.

Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 1st.

WARNING: “SG Americas Securities LLC Has $2.57 Million Position in China Cord Blood Corporation (CO)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/sg-americas-securities-llc-has-2-57-million-position-in-china-cord-blood-corporation-co/1721745.html.

About China Cord Blood Corporation

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Institutional Ownership by Quarter for China Cord Blood Corporation (NYSE:CO)

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.